Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 2750
Single User License Price INR 189750
Corporate User License Price USD 4500
Corporate User License Price INR 310500
Site License Price USD 3500
Site License Price INR 241500
Request a Quote

Report Title

Global Antidepressant Drugs Market Forecast up to 2018 - 2024

Quote Request for License Type
License Type Price  
Single User License USD 2750
Site License USD 3500
Enterprise Wide License USD 4500
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Global Antidepressant Drugs Market Forecast up to 2018 - 2024


Quote Request for License Type
License Type Price  
Single User License USD 2750
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Global Antidepressant Drugs Market Forecast up to 2018 - 2024

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Global Antidepressant Drugs Market Forecast up to 2018 - 2024



Executive Summary

Global Antidepressant Drugs Market-Drivers, Restraints, Opportunities, Trends, and Forecast: 2018-2024

Overview: Depression is a serious mental illness affecting more than 350 million people globally. This is also known as major depression disorder or unipolar depression. According to a report by the Psychiatric Association, nearly 14.8 million adults in the US are suffering from depression. Growing aging population and increasing prevalence of depression are the primary factors driving the global antidepressant drugs market growth. Supportive initiatives from the government & other organizations and increasing clinical trials will provide an opportunity for the market growth in the future.

At the global level, over 300 million people are estimated to suffer from depression, which is equivalent to 4.4% of the world's total population. Only less than 10% of the affected people are treated although there is the availability of branded and effective treatments for depression. The challenges for effective care include lack of capitals, unavailability of qualified health-care providers, and public stigma associated with mental disorders. Along with these, imprecise assessment of the condition is also a challenge faced globally.

Market Analysis: The global antidepressant drugs market is estimated to witness a CAGR of 2.2% during the forecast period 2018-2024. The global antidepressant drugs market is analyzed based on drug class and regions.

Regional Analysis: The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (ROW). North America accounts for the largest share of the antidepressant drugs market, followed by Europe, Asia Pacific, and Rest of the World. North America alone occupies more than 30% of the market, with a significant contribution from the US to the market growth.

Drug Class Analysis: Based on the drug class, the market is segmented into selective serotonin reuptake inhibitors (SSRIs), norepinephrine-dopamine reuptake inhibitors (NDRI), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), and others. SSRIs are the most attractive drug in the market, owing to the highly effective treatment of depression and anxiety.

Key Players: Novartis AG, Allergan Inc., Elli Lilly and Company, AstraZeneca plc, GSK, Otsuka Holdings Co., Ltd., and Johnson & Johnson are the key players in the market. The other prominent players include Pfizer, Shionogi & Co. Ltd., Abbott Laboratories, Takeda Pharmaceutical Co., Ltd., and H. Lundbeck A/S.

Competitive Analysis: Government initiatives have been greatly changing the market scenario. Many initiatives are taken to increase the awareness and reduce the suicidal rate globally. Depression is confined by the mental health Gap Action Programme (mhGAP) of the World Health Organization (WHO) to assists countries to increase their facilities for those suffering from mental disorders, through special aid by healthcare workers. A special transitory is established by WHO for the treatment of depression. The companies are striving to develop innovative drugs to address the unmet needs in the market. For instance, in May 2018, Esketamine Nasal Spray of the Janssen Pharmaceutical Companies of Johnson & Johnson demonstrated rapid enhancements in depressive symptoms in patients with treatment-resistant depression in Phase III trials. Thus, this drug is expected to be one of the bestsellers in the market.

Benefits: The report provides complete details about the usage and adoption rate of antidepressant drugs in various regions. With that, key stakeholders can know about the major trends, drivers, investments, and vertical player's initiatives. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.

Key Stakeholders:

Table of Contents

1 Industry Outlook 10

1.1 Industry Overview 10

1.2 Industry Trends 11

1.3 Total Addressable Market 11

2 Report Outline 13

2.1 Report Scope 13

2.2 Report Summary 13

2.3 Research Methodology 14

2.4 Report Assumptions 15

3 Market Snapshot 16

3.1 Market Definition-Infoholic Research 16

3.2 Segmented Addressable Market 16

3.2.1 Trends in the Antidepressant Drugs Market 17

3.3 Related Markets 18

3.3.1 Neurosurgical Devices 18

3.3.2 Parkinson Drugs 19

3.3.2.1 Trends of Parkinson Diseases Market 20

3.3.3 Neurointerventional Devices 20

3.3.4 Over the Counter Drugs (OTC) 23

4 Market Outline 24

4.1 Antidepressant Drugs Pipeline 24

4.2 Market Segmentation 25

4.3 Porter 5(Five) Forces 26

4.4 PEST Analysis 27

5 Market Characteristics 29

5.1 Market Dynamics 29

5.1.1 Drivers 29

5.1.1.1 Increasing aging population 29

5.1.1.2 Increasing prevalence of Depression 30

5.1.2 Opportunities 31

5.1.2.1 Government Initiatives 31

5.1.2.2 Exhaustive Pipeline and Increasing Clinical Trials 31

5.1.3 Restraints 32

5.1.3.1 Complex drug development process 32

5.1.3.2 Adverse effects of antidepressant drugs 32

5.2 DRO-Impact Analysis 32

5.3 Key Stakeholders 33

6 Drug Class: Market Size and Analysis 35

6.1 Overview 35

6.2 Selective serotonin reuptake inhibitors (SSRIs) 36

6.3 Norepinephrine-dopamine reuptake inhibitor (NDRI) 37

6.4 Serotonin and norepinephrine reuptake inhibitors (SNRIs) 38

6.5 Monoamine oxidase inhibitors (MAOIs) 39

6.6 Tricyclic antidepressants (TCAs) 40

6.7 Others 41

7 Regions: Market Size and Analysis 42

7.1 Overview 42

7.2 North America 44

7.2.1 Overview 44

7.3 Europe 45

7.3.1 Overview 45

7.4 Asia Pacific 47

7.4.1 Overview 47

7.5 Rest of the World 48

7.5.1 Overview 48

8 Competitive Landscape 50

9 Vendor Profiles 53

9.1 AstraZeneca PLC 53

9.1.1 Overview 53

9.1.2 Business Units 55

9.1.3 Geographic Presence 56

9.1.4 Business Focus 57

9.1.5 SWOT Analysis 57

9.1.6 Business Strategies 58

9.2 Eli Lilly & Company Ltd. 59

9.2.1 Overview 59

9.2.2 Business Units 60

9.2.3 Geographic Revenue 61

9.2.4 Business Focus 61

9.2.5 SWOT Analysis 62

9.2.6 Business Strategies 62

9.3 GlaxoSmithKline plc 63

9.3.1 Overview 63

9.3.2 Business Units 67

9.3.3 Geographic Presence 67

9.3.4 Business Focus 68

9.3.5 SWOT Analysis 68

9.3.6 Business Strategies 69

9.4 Johnson & Johnson 69

9.4.1 Overview 69

9.4.2 Business Units 73

9.4.3 Geographic Revenue 74

9.4.4 Business Focus 75

9.4.5 SWOT Analysis 76

9.4.6 Business Strategies 76

9.5 Novartis AG 77

9.5.1 Overview 77

9.5.2 Business Units 80

9.5.3 Geographic Presence 81

9.5.4 Business Focus 82

9.5.5 SWOT Analysis 82

9.5.6 Business Strategy 83

9.6 Otsuka Holdings Co., Ltd. 84

9.6.1 Overview 84

9.6.2 Business Units 86

9.6.3 Geographic Revenue 86

9.6.4 Business Focus 87

9.6.5 SWOT Analysis 87

9.6.6 Business Strategies 88

9.7 Allergan PLC 89

9.7.1 Overview 89

9.7.2 Business Units 90

9.7.3 Geographic Revenue 91

9.7.4 Business Focus 92

9.7.5 SWOT Analysis 92

9.7.6 Business Strategies 93

10 Companies to Watch for 95

10.1 Pfizer, Inc. 95

10.1.1 Overview 95

10.1.2 Highlights 96

10.2 Takeda Pharmaceutical Co. Ltd. 96

10.2.1 Overview 96

10.2.2 Highlights 97

10.3 Shionogi & Co. Ltd. 98

10.3.1 Overview 98

10.3.2 Highlights 98

10.4 Abbott Laboratories 99

10.4.1 Overview 99

10.5 H. Lundbeck A/S 101

10.5.1 Overview 101

Annexure 103

Abbreviations 103

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

Charts

CHART 1 RESEARCH METHODOLOGY OF GLOBAL ANTIDEPRESSANT DRUGS MARKET 14

CHART 2 GLOBAL ANTIDEPRESSANT DRUGS MARKET REVENUE, 2017-2024 (USD MILLION) 17

CHART 3 CLINICAL TRIALS OF NEUROINTERVENTIONAL DEVICES 22

CHART 4 ANTIDEPRESSANT DRUGS PIPELINE 24

CHART 5 SEGMENTATION OF GLOBAL ANTIDEPRESSANT DRUGS MARKET 25

CHART 6 PORTER 5 FORCES OF ANTIDEPRESSANT DRUGS MARKET 26

CHART 7 PEST ANALYSIS OF ANTIDEPRESSANT DRUGS MARKET 27

CHART 8 MARKET DYNAMICS-DRO ANALYSIS 29

CHART 9 WORLD POPULATION AGED 65 YEARS AND ABOVE, 1960-2060 (%) 30

CHART 10 DRO-IMPACT ANALYSIS OF GLOBAL ANTIDEPRESSANT DRUGS MARKET 32

CHART 11 KEY STAKEHOLDERS 34

CHART 12 ANTIDEPRESSANT DRUGS MARKET BY DRUG TYPE SEGMENTATION, 2017-2024 (USD MILLION) 35

CHART 13 ANTIDEPRESSANT DRUGS MARKET REVENUE BY PRODUCTS TYPE, 2017-2024 (USD MILLION) 35

CHART 14 SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) DRUGS MARKET BY TYPES SEGMENTATION, 2017-2024 (USD MILLION) 36

CHART 15 NOREPINEPHRINE-DOPAMINE REUPTAKE INHIBITOR (NDRI) MARKET BY TYPES SEGMENTATION, 2017-2024 (USD MILLION) 37

CHART 16 SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) DRUGS MARKET BY TYPES SEGMENTATION, 2017-2024 (USD MILLION) 38

CHART 17 MONOAMINE OXIDASE INHIBITORS (MAOIS) DRUGS MARKET BY TYPES SEGMENTATION, 2017-2024 (USD MILLION) 39

CHART 18 TRICYCLIC ANTIDEPRESSANTS (TCAS) DRUGS MARKET BY TYPES SEGMENTATION, 2017-2024 (USD MILLION) 40

CHART 19 OTHERS ANTIDEPRESSANT DRUGS MARKET BY TYPES SEGMENTATION, 2017-2024 (USD MILLION) 41

CHART 20 CASES OF DEPRESSIVE DISORDER (MILLIONS), BY WHO REGION IN 2017 (%) 42

CHART 21 ANTIDEPRESSANT DRUGS MARKET BY REGIONAL SEGMENTATION, 2017 VS 2024 (%) 43

CHART 22 ANTIDEPRESSANT DRUGS MARKET REVENUE BY REGIONS, 2017-2024 (USD MILLION) 43

CHART 23 ANTIDEPRESSANT DRUGS MARKET REVENUE IN NORTH AMERICA, 2017-2024 (USD MILLION) 45

CHART 24 PREVALENCE OF CHRONIC DEPRESSION, 2014 46

CHART 25 ANTIDEPRESSANT DRUGS MARKET REVENUE IN EUROPE, 2017-2024 (USD MILLION) 46

CHART 26 ANTIDEPRESSANT DRUGS MARKET REVENUE IN ASIA PACIFIC, 2017-2024 (USD MILLION) 48

CHART 27 ANTIDEPRESSANT DRUGS MARKET REVENUE IN REST OF THE WORLD, 2017-2024 (USD MILLION) 49

CHART 28 ASTRAZENECA PLC: OVERVIEW SNAPSHOT 53

CHART 29 ASTRAZENECA PLC: BUSINESS UNITS 55

CHART 30 ASTRAZENECA PLC: GEOGRAPHIC PRESENCE 56

CHART 31 ASTRAZENECA PLC: SWOT ANALYSIS 57

CHART 32 ELI LILLY & COMPANY LTD.: OVERVIEW SNAPSHOT 59

CHART 33 ELI LILLY & COMPANY LTD.: BUSINESS UNITS 60

CHART 34 ELI LILLY & COMPANY LTD.: GEOGRAPHIC REVENUE 61

CHART 35 ELI LILLY & COMPANY LTD.: SWOT ANALYSIS 62

CHART 36 GLAXOSMITHKLINE PLC: OVERVIEW SNAPSHOT 63

CHART 37 GLAXOSMITHKLINE PLC: BUSINESS UNITS 67

CHART 38 GLAXOSMITHKLINE PLC: GEOGRAPHIC PRESENCE 67

CHART 39 GLAXOSMITHKLINE PLC: SWOT ANALYSIS 68

CHART 40 JOHNSON & JOHNSON: OVERVIEW SNAPSHOT 72

CHART 41 JOHNSON & JOHNSON: BUSINESS UNITS 73

CHART 42 JOHNSON & JOHNSON: GEOGRAPHIC REVENUE 74

CHART 43 JOHNSON & JOHNSON: SWOT ANALYSIS 76

CHART 44 NOVARTIS AG: OVERVIEW SNAPSHOT 77

CHART 45 NOVARTIS AG: BUSINESS UNITS 80

CHART 46 NOVARTIS AG: GEOGRAPHICAL PRESENCE 81

CHART 47 NOVARTIS AG: SWOT ANALYSIS 82

CHART 48 OTSUKA HOLDINGS CO., LTD.: OFFERINGS 84

CHART 49 OTSUKA HOLDINGS CO., LTD.: RECENT DEVELOPMENTS 84

CHART 50 OTSUKA HOLDINGS CO., LTD.: OVERVIEW SNAPSHOT 85

CHART 51 OTSUKA HOLDINGS CO., LTD.: SEGMENTATION 86

CHART 52 OTSUKA HOLDINGS CO., LTD.: GEOGRAPHIC REVENUE 86

CHART 53 OTSUKA HOLDINGS CO., LTD.: SWOT ANALYSIS 87

CHART 54 ALLERGAN PLC: OFFERINGS 89

CHART 55 ALLERGAN PLC: RECENT DEVELOPMENTS 89

CHART 56 ALLERGAN PLC: OVERVIEW SNAPSHOT 90

CHART 57 ALLERGAN PLC: BUSINESS UNITS 90

CHART 58 ALLERGAN PLC: GEOGRAPHIC REVENUE 91

CHART 59 ALLERGAN PLC: SWOT ANALYSIS 92

CHART 60 PFIZER, INC.: RECENT DEVELOPMENTS 95

CHART 61 PFIZER, INC: KEY DEVELOPMENTS 95

CHART 62 ABBOTT LABORATORIES: RECENT DEVELOPMENTS 99

CHART 63 ABBOTT LABORATORIES: KEY DEVELOPMENTS 99

CHART 64 H. LUNDBECK A/S: OVERVIEW 102

CHART 65 H. LUNDBECK A/S: RECENT DEVELOPMENTS 102

Tables

TABLE 1 ASTRAZENECA PLC: OFFERINGS 53

TABLE 2 ASTRAZENECA PLC: RECENT DEVELOPMENTS 54

TABLE 3 ELI LILLY & COMPANY LTD.: PRODUCT OFFERINGS 59

TABLE 4 ELI LILLY & COMPANY LTD.: RECENT DEVELOPMENTS 59

TABLE 5 GLAXOSMITHKLINE PLC: OFFERINGS 63

TABLE 6 GLAXOSMITHKLINE PLC: RECENT DEVELOPMENTS 64

TABLE 7 JOHNSON & JOHNSON: PRODUCT OFFERINGS 70

TABLE 8 JOHNSON & JOHNSON: RECENT DEVELOPMENTS 70

TABLE 9 NOVARTIS AG: OFFERINGS 77

TABLE 10 NOVARTIS AG: RECENT DEVELOPMENTS 78

TABLE 11 TAKEDA PHARMACEUTICAL CO. LTD.: OVERVIEW 97

TABLE 12 TAKEDA PHARMACEUTICAL CO. LTD.: RECENT DEVELOPMENTS 97

TABLE 13 SHIONOGI & CO., LTD.: OVERVIEW 98

TABLE 14 SHIONOGI & CO., LTD.: RECENT DEVELOPMENTS 98

Novartis AG, Allergan Inc., Elli Lilly and Company, AstraZeneca plc, GSK, Otsuka Holdings Co., Ltd., and Johnson & Johnson are the key players in the market. The other prominent players include Pfizer, Shionogi & Co. Ltd., Abbott Laboratories, Takeda Pharmaceutical Co., Ltd., and H. Lundbeck A/S


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand

person